HLS Therapeutics Inc.HLS.TOReports Thu, Nov 12 · Q3 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · hlstherapeutics.com
HLS Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceuticals in the central nervous system and cardiovascular markets. Key products include CLOZARIL (clozapine) for the treatment of psychiatric disorders and VASCEPA (icosapent ethyl) for cardiovascular disease management in Canada and internationally.
Key ratios
Operating cash flow growth
42.0%TTM
2025
114.0%2024
-49.3%2023
-6.8%
FCF / Sales
32.3%TTM
2025
30.5%2024
14.1%2023
25.0%
Net margin
-15.2%TTM
2025
-22.4%2024
-34.7%2023
-43.7%
ROA
-2.0%TTM
2025
-1.7%2024
-2.6%2023
-2.9%
ROE
-14.1%TTM
2025
-18.7%2024
-23.3%2023
-24.7%
Revenue growth
-0.3%TTM
2025
-2.0%2024
-10.2%2023
2.6%
Recent news
HLS Therapeutics Partners with Bayer to Commercialize VERQUVO® in Canada
HLS Therapeutics to Host Q3 2026 Financial Results Conference Call
HLS Therapeutics to Present at the Planet MicroCap Toronto Conference
HLS Therapeutics Announces Board of Directors Changes
HLS Therapeutics Increases Normal Course Issuer Bid
HLS Therapeutics Announces Q2 2026 Financial Results
HLS Therapeutics Secures Major Private Payer Coverage and Unanimous Public Reimbursement Recommendation for NILEMDO in Canada
HLS Therapeutics to Host Q2 2026 Financial Results Conference Call
HLS Therapeutics Reports Annual Meeting Results
HLS Therapeutics Announces Normal Course Issuer Bid
Track HLS.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer